Redx Pharma Plc announced the appointment of Dr. Rob Scott as a Non-Executive Director with immediate effect. Dr. Scott brings extensive clinical development and regulatory experience to the Board, having held senior leadership positions in global pharma for over thirty years. Most recently, Dr. Scott retired as Chief Medical Officer at AbbVie, where he oversaw 14 major regulatory approvals including Venclexta, Orilissa, Skyrizi and Rinvoq.
Redx Pharma Plc London S.E.
Equities
REDX
GB00BSNB6S51
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
15 GBX | +31.58% | -.--% | -31.82% |
1st Jan change | Capi. | |
---|---|---|
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- 0RX Stock
- REDX Stock
- News Redx Pharma Plc
- Redx Pharma plc Appoints Dr. Rob Scott as a Non-Executive Director